This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie (ABBV) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 0.45% and 0.03%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.
Regeneron Expands Agreement to Develop Coronavirus Therapy
by Zacks Equity Research
Regeneron (REGN) expands its agreement with U.S. Department of Health and Human Services for development of a therapy for newly found coronavirus.
Can Humira/Cancer Drugs Help AbbVie (ABBV) Beat Q4 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs might demonstrate strong growth.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $82.30, marking a +1.58% move from the previous day.
Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock Up
by Zacks Equity Research
Vaxart (VXRT) begins a program to develop a vaccine candidate to counter the new coronavirus infection. Shares jump.
Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study
by Zacks Equity Research
Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.
Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat
by Zacks Equity Research
Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.
J&J (JNJ) Plans to Develop Vaccine for New Coronavirus
by Zacks Equity Research
J&J (JNJ) is looking to develop a vaccine for the new coronavirus infection. Its drug Erleada's label is expanded to include new prostate cancer patient population in Europe.
Biogen (BIIB) Surpasses Q4 Earnings and Sales Estimates
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The company expects decline in sales and earnings in 2020.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $83.77, moving -0.3% from the previous trading session.
Allergan to Divest Brazikumab, Zenpep to Close AbbVie Merger
by Zacks Equity Research
Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.
3 Top Dividend Stocks to Maximize Your Retirement Income - January 27, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
The Market Timing Secrets No One Talks About - January 27, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
What Lies Ahead for Healthcare ETFs in Q4 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
How Trading Your Own Retirement Can Fleece Your Financial Future - January 23, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $87.20, marking a -0.9% move from the previous day.
J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short
by Zacks Equity Research
J&J (JNJ) comes up with mixed fourth-quarter 2019 results.
5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Simple Secrets Anyone Can Use to Reach Early Retirement - January 22, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe
by Zacks Equity Research
Roche (RHHBY) obtains approval for Polivy in Europe for the treatment of adult patients with R/R DLBCL.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - January 20, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Retirees Should Know These 3 Facts About Required Minimum Distributions - January 17, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
by Kinjel Shah
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.